Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG). It isn ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› by Ivy Elrod Trading city life for a farm in the Catskills, cookbook author ...